| Literature DB >> 34995374 |
Manuel Maria Ianieri1, Diego Raimondo2, Andrea Rosati1, Laura Cocchi2, Rita Trozzi1, Manuela Maletta2, Antonio Raffone2,3, Federica Campolo1, Giuliana Beneduce1, Antonio Mollo4, Paolo Casadio2, Ivano Raimondo5, Renato Seracchioli2, Giovanni Scambia1.
Abstract
OBJECTIVE: To evaluate the functional outcomes of nerve-sparing surgery for deep infiltrating endometriosis (DIE) with or without posterolateral parametrectomy.Entities:
Keywords: deep infiltrative endometriosis; functional outcomes; nerve-sparing; parametrectomy; pelvic nerves
Mesh:
Year: 2022 PMID: 34995374 PMCID: PMC9542420 DOI: 10.1002/ijgo.14089
Source DB: PubMed Journal: Int J Gynaecol Obstet ISSN: 0020-7292 Impact factor: 4.447
Clinical and demographic characteristics of parametrectomy group (P) and non‐parametrectomy group (NP)
| Group P ( | Group NP ( |
| |
|---|---|---|---|
| Age, years | 38 (32.5–43) | 38 (34–46) | 0.305 |
| BMI | 22 (20–24.8) | 25 (22.8–29) | 0.002 |
| Previous surgery for endometriosis | 19 (27.5) | 14 (45.2) | 0.083 |
| Stage of disease accordingto rASRM classification | |||
| IV | 37 (53.6) | 16 (51.6) | 0.598 |
| III | 30 (43.5) | 15 (48.4) | |
| II | 2 (2.9) | 0 (0) | |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); r‐ASRM, revised American Society for Reproductive Medicine.
Values are presented as median (range) or as number (percentage).
Surgical details of parametrectomy group (P) and non‐parametrectomy group (NP)
| Group P ( | Group NP ( |
| |
|---|---|---|---|
| Bowel surgery | 45 (65.2) | 23 (74.2) | 0.373 |
| Rectal shaving | 21 (30.4) | 10 (32.3) | 0.855 |
| Segmental bowel resection | 18 (26.1) | 8 (25.8) | 0.976 |
| Discoid resection | 10 (14.5) | 6 (19.4) | 0.540 |
| Type of bowel anastomosis | |||
| Termino‐terminal | 5 (7.6) | 4 (15.4) | 0.513 |
| Latero‐terminal | 9 (13.6) | 5 (19.2) | |
| Latero‐lateral | 1(1.5) | 0 (0) | |
| Hysterectomy | 16 (23.2) | 8 (25.8) | 0.777 |
| Ileostomy | 5 (7.2) | 1 (3.2) | 0.434 |
| Endometrioma stripping | 33 (47.8) | 12 (38.7) | 0.397 |
| Ureterolysis | 58 (84.1) | 22 (71) | 0.130 |
| Ureteral resection and reimplantation | 3 (4.3) | 0 (0) | 0.550 |
| Partial resection of the bladder | 5 (7.2) | 2 (6.5) | 0.999 |
| Excision of vaginal nodule | 11 (15.9) | 4 (12.9) | 0.694 |
| Estimated blood loss, ml | 120 (100–150) | 120 (120–150) | 0.294 |
| Operative time, min | 180 (127–250) | 154 (130–195) | 0.047 |
Values are presented as median (range) or as number (percentage).
Postoperative variables of parametrectomy group (P) and non‐parametrectomy group (NP)
| Group P ( | Group NP ( |
| |
|---|---|---|---|
| Days of hospitalization | 6 (4–8) | 7 (4–8) | 0.378 |
| Fever | 6 (8.7) | 3 (9.7) | 0.999 |
| Blood transfusion | 5 (7.2) | 1 (3.2) | 0.663 |
| Hemoperitoneum | 1 (1.4) | 0 (0) | 0.999 |
| Urinary tract infection | 4 (5.8) | 1 (3.2) | 0.999 |
| Urinary voiding dysfunction | 6 (8.7) | 0 (0) | 0.173 |
| Anastomotic leakage | 0 (0) | 2 (6.5) | 0.094 |
| Complications according to Clavien‐Dindo classification | |||
| Grade 1 | 4 (5.8) | 0 (0) | 0.205 |
| Grade 2 | 14 (20.3) | 3 (9.7) | |
| Grade 3 | 1 (1.4) | 2 (6.5) | |
Values are presented as median (range) or as number (percentage).
Calculate considering the absolute numbers of each complication.
Calculate considering only the maximum Clavien‐Dindo grade for each patient.
Functional data and pain symptoms at preoperative evaluation and 3‐month follow up of parametrectomy group (P) and non‐parametrectomy group (NP)
| Preoperative | Postoperative | |||||
|---|---|---|---|---|---|---|
| Group P ( | Group NP ( |
| Group P ( | Group NP ( |
| |
| Dyschezia VAS | 0 (0–10) | 3 (0–10) | 0.194 | 0 (0–9) | 0 (0–10) | 0.783 |
| Dysmenorrhea VAS | 8 (0–10) | 7 (0–10) | 0.230 | 0 (0–10) | 0 (0–8) | 0.228 |
| Dysuria VAS | 0 (0–9) | 0 (0–7) | 0.224 | 0 (0–8) | 0 (0–1) | 0.415 |
| Dyspareunia VAS | 6 (0–10) | 3 (0–10) | 0.055 | 0 (0–8) | 0 (0–3) | 0.049 |
| Chronic pelvic pain VAS | 5 (0–10) | 3 (0–10) | 0.595 | 0 (0–8) | 0 (0–8) | 0.316 |
| KESS total score | 15 (3–29) | 14 (2–25) | 0.609 | 11 (0–28) | 10 (0–31) | 0.861 |
| GIQLI total score | 87 (42–129) | 90 (8–105) | 0.849 | 104 (59–139) | 105 (60–138) | 0.602 |
| Constipation (KESS ≥10) | 48 (69.6) | 24 (77.4) | 0.419 | 41 (59.4) | 19 (61.3) | 0.860 |
| FSFI total score | 21.6 (2–34) | 23.7 (14–31) | 0.101 | 24.4 (2–36) | 26.1 (2–31) | 0.397 |
| BFLUTS total score | 7 (0–30) | 3 (1–58) | 0.093 | 6 (0–34) | 3 (1–36) | 0.143 |
| FSD (FSFI score <26.5) | 45 (65.2) | 20 (64.5) | 0.946 | 39 (56.5) | 10 (32.3) | 0.025 |
Abbreviations: BFLUTS, the Bristol Female Lower Urinary Tract Symptom Questionnaire; FSD, female sexual dysfunction; FSFI, the Female Sexual Function Index; GIQLI, the Gastrointestinal Quality of Life Index; KESS, Knowles‐Eccersley‐Scott‐Symptom Questionnaire; VAS, visual analog scale.
Values are presented as median (range; expressed as minimum‐maximum) or as number (percentage).
Analysis of functional outcomes and pain symptoms with the two way mixed model analysis of variance for repeated measures
| Group P ( | Group NP ( | Time main effect | Group main effect | |||
|---|---|---|---|---|---|---|
| Preoperative | Postoperative | Preoperative | Postoperative | |||
| Dyschezia VAS | 3.2 ± 3.6 | 0.8 ± 2.0 | 4.2 ± 3.5 | 1.0 ± 2.5 | <0.001 | 0.203 |
| Dysmenorrhea VAS | 6.5 ± 3.6 | 1.3 ± 2.6 | 5.5 ± 3.8 | 0.7 ± 1.8 | <0.001 | 0.124 |
| Dysuria VAS | 1.2 ± 2.6 | 0.4 ± 1.4 | 0.5 ± 1.7 | 0.0 ± 0.2 | 0.026 | 0.079 |
| Dyspareunia VAS | 5.2 ± 3.6 | 0.9 ± 2.2 | 3.7 ± 3.5 | 0.1 ± 0.5 | <0.001 | 0.015 |
| Chronic pelvic pain VAS | 4.1 ± 3.7 | 1.0 ± 2.1 | 3.5 ± 3.9 | 0.6 ± 1.9 | <0.001 | 0.358 |
| KESS total score | 14.4 ± 6.3 | 11.8 ± 6.2 | 13.6 ± 6.3 | 12.0 ± 7.9 | 0.014 | 0.778 |
| GIQLI total score | 85.4 ± 19.2 | 101.5 ± 18.5 | 82.9 ± 20.0 | 102.5 ± 19.8 | <0.001 | 0.838 |
| FSFI total score | 19.4 ± 9.8 | 21.6 ± 10.8 | 23.8 ± 3.7 | 23.7 ± 8.1 | 0.354 | 0.083 |
| BFLUTS total score | 9.1 ± 7.7 | 6.8 ± 5.6 | 8.3 ± 11.7 | 6.8 ± 7.6 | 0.006 | 0.788 |
Abbreviations: BFLUTS, the Bristol Female Lower Urinary Tract Symptom Questionnaire; FSFI, the Female Sexual Function Index; GIQLI, the Gastrointestinal Quality of Life Index; KESS, Knowles‐Eccersley‐Scott‐Symptom Questionnaire; NP, non‐parametrectomy group; P, parametrectomy group; VAS, visual analog scale.
Values are presented as mean ± standard deviation.